$55.3 Million is the total value of Opus Point Partners Management, LLC's 55 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
UTHR | New | UNITED THERAPEUTICS CORP DEL | $279,000 | – | 3,498 | +100.0% | 0.50% | – |
ALKS | New | ALKERMES PLC | $227,000 | – | 11,632 | +100.0% | 0.41% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2019-11-14 |
13F-HR | 2019-08-14 |
13F-HR | 2019-05-15 |
13F-HR | 2019-02-14 |
13F-HR | 2018-11-14 |
13F-HR | 2018-08-14 |
13F-HR | 2018-05-15 |
13F-HR | 2018-02-14 |
13F-HR/A | 2017-11-17 |
13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.